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Introduction: The molecular mechanisms of oncogenesis in me-
sothelioma involve the loss of negative regulators of cell growth
including p16INK4a. Absence of expression of the p16INK4a gene
product is exhibited in virtually all mesothelioma tumors and cell
lines examined to date. Loss of p16INK4a expression has also been
frequently observed in more common neoplasms such as lung cancer
as well. In a wide variety of these malignancies, including lung cancer,
p16INK4a expression is known to be inactivated by hypermethylation of
the first exon. This project (CALGB 159904) intended to test the
hypothesis that in mesothelioma loss of p16INK4a via methylation
would correlate with response to the cytidine analog and methylation
inhibitor dihydro-5-azacytidine (DHAC).
Methods: Using tissue samples from CALGB 8833 and 9031, two
clinical studies which used DHAC based therapy in mesothelioma, this
study tested the hypothesis that tumors possessing methylation of
p16INK4a would have a better response and survival following DHAC
treatment than their nonmethylated counterparts.
Results: Methylation of p16INK4a was identified in 4 of the 20 speci-
mens. Although there was a trend towards improved survival the result
was not statistically significant.
Conclusions: There was no significant correlation between the pres-
ence of p16INK4a methylation and response to DHAC therapy or overall
survival.
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Malignant mesothelioma, a cancer strongly related to ahistory of asbestos exposure, is newly diagnosed in more
than 2000 patients annually in the United States.1 One of the
most common cytogenetic abnormalities found in mesothelioma
cell lines and tumors is a homozygous or hemizygous disruption
of the 9p21 loci.2 Several cell cycle regulatory genes are located
at this loci including the cyclin-dependent kinase (Cdk) inhibi-
tors p16INK4a, p15INK4b, and p14ARF.3 The p16INK4a protein
inhibits the Cdk-mediated hyperphosphorylation of pRb, result-
ing in inhibition of the G1 to S transition. In mesothelioma
tumors, p16INK4a is disrupted in a variety of mechanisms includ-
ing gene alterations, deletions, methylation of promoter regions
or rare point mutations.4 When examined the level of protein
expression most of these alterations lead to the loss of the
p16INK4a gene product in almost all mesothelioma samples.5
Conversely, wild-type pRb is retained in all of the tumors.
Reexpression of the p16INK4a protein in mesothelioma cells has
been associated with cell cycle arrest and subsequent cell
death.6,7 One mechanism in cancer for the loss of p16INK4a gene
expression is the hypermethylation of the CpG islands. Methyl-
ation of p16INK4a has been observed in mesothelioma cell lines
and tumors, although it occurs at a relatively low rate. Studies on
mesothelioma and p16INK4a methylation have found a range
from less than 10% of tumors with methylated p16INK4a,4,8 to up
to 19% of mesothelioma samples possessing methylation of
p16INK4a.9
Cytidine analog drugs have been shown to inhibit DNA
methylation and mediate reexpression of p16INK4a in both
small cell and non-small cell lung cancer.10 In mesothelioma,
p16INK4a was reexpressed in a methylated cell line with the
addition of the methylation inhibitor, 5-aza-2-deoxycytidine.9
The class of cytidine analogs, which can inhibit DNA methyl-
ation, has been extensively tested in cancers including mesothe-
lioma. In two previous clinical trials (CALGB 8833 and 9031),
the cytidine analog dihydro-5-azacytidine (DHAC) was tested as
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a potential therapeutic agent in 70 patients with mesothelioma.
DHAC, a pyrimidine nucleoside analog of cytidine, is incorpo-
rated into DNA and inhibits DNA methylation, an important
step in gene expression. DHAC also competes with cytidine
triphosphate for incorporation into RNA, leading to ribosomal
degradation and defective protein synthesis.11,12 The response
rate to DHAC in both of these CALGB trials was only 17%,
however, there were several durable responses suggesting that a
small percentage of the mesothelioma tumors may have revers-
ible DNA methylation of key growth regulatory genes.11,12 In
the current study (CALGB 159904), we examined the methyl-
ation status of p16INK4a in tumors obtained from these two
CALGB phase II trials to determine if hypermethylation of the
p16INK4a gene correlates with a response to DHAC therapy and
overall survival.
MATERIALS AND METHODS
Tumor Samples
CALGB 8833 and CALGB 9031 were studies of the
cytidine analog DHAC in mesothelioma.11,12 In these two
clinical trials in mesothelioma, the cytidine analog DHAC
had been found to induce clinical responses in approximately
17% of patients with mesothelioma treated with this drug,
including several prolonged complete responses.11,12 Submis-
sion of tissue was required for these studies and all tissues
were archived at the CALGB Pathology Coordinating Office.
CALGB 8833 used DHAC therapy alone, while CALGB
9031 used the drug in combination with cis-platinum. In
CALGB 8833 DHAC was given by continuous 120-hour infu-
sion at 1500 mg/m2/d every 21 days. Patients were continued on
therapy until disease progression or intolerable toxicity. The
overall response rate was 17% (7 of 41 patients) including one
complete response. In CALGB 9031 DHACwas given at a dose
of 1500 mg/m2/24 hours by continuous intravenous infusion for
a total of 120 hours. Cis-platinum was given concurrently at a
dose of 15 mg/m2/d by 1-hour infusion daily for 5 days during
the DHAC infusion. Cycles were repeated at 21-day intervals.
All patients signed informed consent for these studies. The
overall objective response rate was 5 of 29 (17%) with no
complete responses. Because of the low response rate, further
studies of DHAC in mesothelioma were abandoned. However,
in light of the several durable responses observed in these
studies, it was felt to be important to attempt to identify if a
molecular surrogate could predict for response to therapy. A
total of only 20 tumor samples out of 70 patients enrolled on
CALGB 8833 and 9031 were available for the analysis. Most of
these were in the form of paraffin-embedded cell block making
microdissection difficult. The reasons for the poor rate of tissue
submission are not entirely clear, although it should be noted
that the first of these studies was initiated almost 20 years ago
before reorganization of the current CALGB tissue core facility.
Table 1 lists the patient characteristics of the samples available
for study. Additional information such as exposure history was
not obtained. All patients were dead at the time of the present
analysis.
Evaluation for Response
The final results of CALGB 8833 and CALGB 9031
were previously published.11,12
Complete response was defined as the disappearance of
all measurable or evaluable disease, signs, symptoms, and
biochemical changes related to tumor for more than 4 weeks,
during which no new lesions appeared. Partial response was
defined as a reduction of greater than 50% in the sum of the
products of two perpendicular diameters of all measurable
lesions lasting more than 4 weeks, during which no new
lesions appeared or existing lesions became larger. Regres-
sion of evaluable disease was defined as a definite decrease in
tumor size agreed on by two independent investigators, with
no new lesion appearing for more than 8 weeks. Disease was
considered stable if no new lesions appeared for more than 8
weeks, there were was an increase of less than 25% in the
sum of the products of diameters of measurable disease, and
no clear change occurred in evaluable tumor. Progression was
the designation if new disease appeared or if there was
definite increase in evaluable disease or an increase of more
than 25% in measurable disease. Survival was evaluated as
overall survival and not progression-free survival. Chest
radiographs and computed tomography scans of the chest
were obtained at baseline and after every two cycles of
therapy.
Genomic DNA Preparation
All laboratory studies were carried out and analyzed in
the laboratory of Robert Kratzke. DNA was extracted from
tumor tissue in the paraffin wax slices using the EX-WAX kit
(Chemicon International) following the manufacturer’s in-
structions. Sections of the tumors were examined prior to
extraction by hematoxylin and eosin staining to assure the
presence of mesothelioma in the specimen. The resulting DNA
pellet was washed with 1 ml of room temperature 70% ETOH
and microcentrifuged. The pellet was dried in a Speedvac
TABLE 1. Patient Characteristics
N (%)
Gender
Male 14 (70)
Female 6 (30)
Age
40 1 (5)
40–49 3 (15)
50–59 3 (15)
60–69 7 (35)
70–79 5 (25)
80 1 (5)
Median 64.5 (min, 23; max, 81)
Race
White 19 (95)
Black or African American 1 (5)
Performance status
0 5 (25)
1 13 (65)
2 2 (10)
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evaporator and then dissolved in 50 l H2O. Samples were
stored at 20°C. DNA from control cell lines was obtained as
previously described using standard proteinase K digestion fol-
lowed by phenol/chloroform extraction.9 The pellet was dried in
a Speedvac evaporator and then dissolved in 50 l water.
Samples were stored at 20°C.
Methylation-Specific PCR
Methylation-specific PCR was used for p16INK4a as
described by Herman et al.13 In this method, DNA is modified
with sodium bisulfite, converting all unmethylated cytosines
to uracil. Methylated cytosines are protected by the methyl
groups and thus are not converted by treatment with sodium
bisulfite. Following PCR, the uracil residues will be repli-
cated as thymidine. Therefore, the DNA sequences of meth-
ylated and unmethylated regions will be different after bisul-
fite treatment. Specific primers designed for the analysis of
methylated and unmethylated p16INK4a DNA are as previ-
ously described.13 Briefly, 2 l of genomic DNA was resus-
pended in 50 l H2O and denatured in 0.2 M of NaOH at
37°C for 10 minutes. Thirty microliters of freshly made 10
mM hydroquinone and 520 l of 3 M sodium bisulfite (pH 5)
were added to the above solution and incubated under mineral
oil at 50°C for at least 16 hours. The modified DNA was
purified by Wizard DNA Clean-Up kit (Promega) and eluted
into 50 l of H2O. The DNA was denatured at room tem-
perature for 5 minute in 0.3 M NaOH, followed by ethanol
precipitation. The precipitated DNA was resuspended in 30
l of dH2O and stored at 20°C. The PCR reaction was
started at 94°C for 4 minutes then 35 cycles of amplification
(95°C/1 min, 60°C/1 min, 72°C/1 min), followed by the
extension of 72°C for 4 minutes. using a Progene Techne
thermal cycler. The PCR products were analyzed by electro-
phoresis on an 8% DNA nondenaturing polyacrylamide gel.
The unmethylated band runs as a 151 base pair band, whereas
the methylated samples run as a 150 base pair band.13 The
DNA bands were visualized by silver staining. Correlation
was determined by Fisher exact test while analysis between
individual characteristics and methylation was carried out
with Cox proportional analysis. All experiments were carried
out in triplicate each time with appropriate positive and
negative controls. DNA from mesothelioma cell line H2596,
which has been previously identified as positive for p16INK4a
methylation,9 was used as a positive control. DNA from a
p16INK4a methylation negative cell line (H2009) was used as
a negative control.
RESULTS
All statistical analyses were performed by CALGB
statisticians. In the 20 samples available for analysis, the pres-
ence of p16INK4a methylation was identified in 4 (20%). the
number of samples available for analysis was fewer than antic-
ipated. Nonetheless, the 20% value is approximately equal to
that previously identified in single institution studies.9 Using
methylation-specific PCR13 the presence of p16INK4a methyl-
ation was easily identified on silver stained gels (Figure 1).
Contrary to the initial hypothesis, there was no statis-
tically significant association between p16INK4a methylation
and best response (CR/PR/regression versus other) according
to Fisher exact test (2-sided p  0.3684) (Table 2). In
addition, there was no statistically significant association
between p16INK4a methylation status and disease control
(CR/PR/regression/stable versus other) with a 2-sided p 
1.000 (Table 2). In addition, there was no statistically signif-
icant association between any of the baseline variables listed
in Table 1 and overall survival at a significance level of 0.05
as evidenced by Cox’s proportional hazard models. The
model fitted was a multivariate model with survival time as
outcome. The covariates included are age (60 versus 60),
gender, race, performance status (0 versus 1), weight loss
( 5%, versus 5%), and p16INK4a methylation status.
The median survival time for p16INK4a methylation posi-
tive tumors is 11.06 months (95% confidence interval: 0.23-not
evaluable); the median survival time for p16INK4a methylation
negative is 3.88 months (95% confidence interval: 1.74–10.3)
(Figure 2). Independent of response rate, there was a trend that
FIGURE 1. Assay for p16INK4a methylation. The presence of
methylated p16INK4a (m) or unmethylated p16INK4a (u) is
indicated by the presence of the respective 151 or 150 base
pair (bp) PCR product. The H2009 lung cancer cell line is a
p16INK4a methylation negative control (u) while the H2596
mesothelioma cell line is a positive control (m) for methyl-
ation of p16INK4a (Wong L, Zhou J, Anderson D, Kratzke RA.
Inactivation of p16(INK4a) expression in malignant mesothe-
lioma by methylation. Lung Cancer 2002;38:131–136). Two
representative mesothelioma tumors are shown (tumor 1
and tumor 2). Tumors positive for methylation such as tu-
mor 2 will usually demonstrate the presence of both methyl-
ated and unmethylated p16INK4a DNA indicating the pres-
ence of both cancerous and noncancerous tissues in the
sample.
TABLE 2. Correlation of Response or Disease Control with
p16INK4a Methylation
p16INK4a N
Fisher
Exact
Test (p)
Response (CR, PR,
regression vs. other)
0.3685
No Methylated 3
No Not methylated 15
Yes Methylated 1
Yes Not methylated 1
Disease control (CR, PR,
regression, stable vs.
other)
1.000
No Methylated 2
No Not methylated 7
Yes Methylated 2
Yes Not methylated 9
CR, complete response; PR, partial response.
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patients with positive p16INK4a methylated tumors living longer
than those without (hazard ratio  0.42, 95% confidence inter-
val: 0.12–1.46) (Figure 2). However, the association between
overall survival and p16INK4a methylation status was not statis-
tically significant, as evaluated by log-rank test (p  0. 1708).
Similarly, as shown in the multivariate analysis using Cox’s
proportional hazard regression, there was no statistically signif-
icant association between methylation status and overall survival
(hazard ratio  0.36, p  0.1271) after adjusting for sex (p 
0.0807) and weight loss (p  0.1935) in the final model.
Methylation of p16INK4a could be a potential marker for re-
sponse to DHAC therapy and therefore there may be a possible
correlation with overall survival; however, this did not reach
statistical significance. Nevertheless, given the small sample size
(20 samples) and the relatively low prevalence of methylation
(20%) in this study, these statistically negative findings need
interpretation with caution.
DISCUSSION
Alterations of epigenetic control as a significant event
in carcinogenesis have become an accepted paradigm in
cancer biology and chemotherapeutic agents that potentially
modulate this phenomenon have shown utility in leukemia
and myelodysplastic syndromes.14 DHAC was an early cyti-
dine analog to enter clinical trials. CALGB 8833 and CALGB
9031 tested this promising agent in mesothelioma with mod-
est benefit and a low response rate (17%). Because of this, the
CALGB did not pursue further studies of this agent in mesothe-
lioma. In these studies, however, durable responses in a low
number of patients raising the possibility that a subset of me-
sothelioma patients could derive substantial benefit from treat-
ment with this class of agents. One attractive hypothesis is that
correction of p16INK4a methylation in mesothelioma patients
would be associated with response to therapy and improved
survival. In myelodysplastic syndromes, for example, in patients
benefiting from treatment with the cytidine analog 5-azacytidine,
widespread demethylation can be demonstrated following treat-
ment.15 Additional support for active reversal of methylation in
mesothelioma patients treated with DHAC comes from the
observation that induction of fetal hemoglobin expression
(known to be regulated by epigenetic mechanisms16) resulted in
mild polycythemia.11,12 In mesothelioma, it will be interesting to
note the status of gene methylation in new studies going forward
looking at novel agents such as histone deacetylase inhibitors
which directly impacts the methylation status of critical genes.17
No significant correlation was found between the pres-
ence of p16INK4a methylation and response to treatment, or
overall survival, in this study. Although there was a trend
towards improved survival independent of response to ther-
apy (Figure 2) that failed to reach statistical significance. It is
interesting to note that hypermethylation in mesothelioma has
proved to have independent prognostic significance in a
variety of loci.18,19 The lack of evidence for a correlation of
response to therapy and the presence of p16INK4a methylation
argues for an alternative target for this therapy in mesotheli-
oma. If future studies are carried out with methylation inhib-
itors in mesothelioma it would be appropriate to incorporate
a proteomic approach for biomarker and target discovery.
Increasingly, the diverse nature of the acquired genetic
and epigenetic molecular abnormalities in solid tumors is
being identified and incorporated into tailored therapy for
diseases such as lung and breast cancer. Mesothelioma will
also likely be best treated by therapies targeting aberrant
molecular pathways which may differ from tumor to tumor.
Paraffin embedded tissue was available on only 20 of the 70
patients enrolled on CALGB 8833 and CALGB 9031 patients
even though submission of these samples was a requirement
for the study. It is possible a larger study cohort could have
lead to different conclusions. Future clinical studies in me-
sothelioma, as well as all solid tumors, should be built around
required submission of adequate samples to allow for studies
to identify novel targets for therapeutic intervention. The
systematic collection and storage of tissue and blood samples
should be considered a standard component for all mesothe-
lioma treatment studies.
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